Linotroban is a potent and selective thromboxane (TXA2) receptor antagonist. It is known as a novel antithrombotic agent. Linotroban ingestion reduced significantly the thrombus volume. The coagulation, as measured by fibrin deposition and FPA plasma levels, was not significantly affected by Linotroban. It appears that the thromboxane A2 receptor antagonist linotroban reduces the thrombotic response by primarily impairing the platelet function at arterial blood flow conditions, and particularly at high wall shear rates. Linotroban had been in phase II clinical trial for the treatment of thrombosis. But this research was discontinued.